Second Genome Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
M&A
Second Genome General Information
Description
Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision therapies and biomarkers. The company's platform uses a microbiome data platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites from the microbiome, enabling researchers to develop medicines through microbiome science.
Contact Information
Website
www.secondgenome.comCorporate Office
- 1000 Marina Boulevard
- Suite 500
- Brisbane, CA 94005-1838
- United States
Corporate Office
- 1000 Marina Boulevard
- Suite 500
- Brisbane, CA 94005-1838
- United States
Second Genome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 000.00 | Completed | Clinical Trials - Phase 2 | |||
| 9. Secondary Transaction - Private | 01-Sep-2021 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 8. Later Stage VC (Series B) | 15-Mar-2019 | 0000 | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
| 7. Grant | 01-Jan-2019 | 00.000 | 000.00 | Completed | Startup | |
| 6. Accelerator/Incubator | 14-Jun-2017 | 000.00 | Completed | Startup | ||
| 5. Later Stage VC (Series B) | 14-May-2017 | 000.00 | 000.00 | 0000 | Completed | Startup |
| 4. Grant | 01-Jan-2017 | 00000 | 000.00 | Completed | Startup | |
| 3. Early Stage VC (Series A) | 07-Jun-2013 | 00.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 09-Aug-2011 | $5M | $6.24M | 000.00 | Completed | Startup |
| 1. Seed Round | 07-Jul-2010 | $1.24M | $1.24M | 00.00 | Completed | Startup |
Second Genome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed | 5,607,290 | $0.000100 | $0.02 | $0.22 | $0.22 | 1x | $0.22 | 1.45% |
Second Genome Comparisons
Industry
Financing
Details
000000
000000
Second Genome Competitors (36)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sphere Fluidics | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 000.00 | 0000000000 0 | 000.00 |
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 0000000000 | 00000 |
| Fluxion (Diagnostic Equipment) | Formerly VC-backed | Alameda, CA | 00 | 000.00 | 000000&0 | 000.00 |
| Locanabio | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 0000000000 0 | 00000 |
| Intus Biosciences | Venture Capital-Backed | Farmington, CT | 00 | 000.00 | 0000000000 0 | 000.00 |
Second Genome Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Second Genome Patents
Second Genome Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021367318-A1 | Methods for treating autism spectrum disorder | Pending | 19-Oct-2020 | 00000000 | |
| EP-4228666-A1 | Methods for treating autism spectrum disorder | Pending | 19-Oct-2020 | 000000000 | |
| US-20240000860-A1 | Methods for treating autism spectrum disorder | Pending | 19-Oct-2020 | 000000000 | |
| EP-4161560-A2 | Peptides for immunotherapy | Pending | 08-Jun-2020 | 000000000000 | |
| US-20230035667-A1 | Methods and compositions for treating type 2 diabetes | Pending | 17-Jan-2020 | A61K35/741 |
Second Genome Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Second Genome FAQs
-
When was Second Genome founded?
Second Genome was founded in 2009.
-
Who is the founder of Second Genome?
Todd DeSantis, Gary Andersen Ph.D, Janet Warrington Ph.D, and Corey Goodman Ph.D are the founders of Second Genome.
-
Where is Second Genome headquartered?
Second Genome is headquartered in Brisbane, CA.
-
What is the size of Second Genome?
Second Genome has 14 total employees.
-
What industry is Second Genome in?
Second Genome’s primary industry is Drug Discovery.
-
Is Second Genome a private or public company?
Second Genome is a Private company.
-
What is Second Genome’s current revenue?
The current revenue for Second Genome is 000000.
-
How much funding has Second Genome raised over time?
Second Genome has raised $98.8M.
-
Who are Second Genome’s competitors?
Sphere Fluidics, Vedanta Biosciences, Fluxion (Diagnostic Equipment), Locanabio, and Intus Biosciences are some of the 36 competitors of Second Genome.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
